Endpoints News
Custom RNA therapies get ARPA-H funds Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M Tue W Th F
1 September, 2026
GLOBAL PHARMA AND BIOTECH SUMMIT - Rewriting the rules of growth, access and innovation - Register now
Drugs worth $180bn in annual revenue are heading off patent, and the industry holds an estimated $1.3tn to fill the gap. Hear how leaders from Novartis, Novo Nordisk and GSK are positioning for what comes next. Register now.
top stories
1. Three takeaways from the latest White House drug pricing event
2. ARPA-H awards $125M for manufacturing custom RNA therapies on demand
3. Arsenal Biosciences cuts ‘majority’ of staff in move to in vivo CAR-T
4. Three deaths in CAR-T trials prompt halt by Novartis; Bristol Myers programs also paused
5. Lilly’s dealmaking spreads the wealth among a broad set of biotech venture investors
6. GSK to launch Phase 3 test of mRNA flu vaccine with newer formulation
7. Novartis' Rhapsido safer than rivals, Phase 3 multiple sclerosis data suggest
more stories
 
Max Bayer
.

At this point, we know how these 'most favored nation' deals shape up. And yesterday, it was who wasn't there that stuck out to me. Some of the largest mid-cap companies sat out this round, and at least one company not in attendance said that, actually, it has a pricing deal as well.

I was also interested to hear an update on the CMS bridge program as well as from Trump's new FDA pick. I detail those takeaways in my story this afternoon. 

.
Max Bayer
Senior Reporter, Endpoints News
Company executives joined President Donald Trump and top health officials at a drug pricing event on Monday. (Credit: AP Photo/Jacquelyn Martin)
1
by Max Bayer

Pres­i­dent Don­ald Trump an­nounced vol­un­tary drug pric­ing deals with nine new com­pa­nies on Mon­day, for the first time veer­ing out­side of the orig­i­nal crop of...

Read the full story
2
by Ryan Cross

The dream of mak­ing per­son­al­ized ge­net­ic med­i­cines at a mo­ment’s no­tice just got a ma­jor in­fu­sion of fund­ing from the fed­er­al gov­ern­ment.

Five groups were...

Read the full story
3
by Anna Brown

Rough­ly a year af­ter shed­ding half of its work­force, Ar­se­nal Bio­sciences is trim­ming its head­count again by let­ting go of “the ma­jor­i­ty” of its staffers...

Read the full story
4
by Nicole DeFeudis

Three pa­tients died in No­var­tis tri­als of its CD19-di­rect­ed CAR-T treat­ment fol­low­ing a dan­ger­ous im­mune sys­tem re­sponse, and a sim­i­lar ther­a­py from Bris­tol My­ers Squibb...

Read the full story
women in BIOPHARMA '26 - Register Now
Twenty new honorees join the 140-plus women Endpoints News has recognized for reshaping biopharma. How did they get there, and what's changed? Join us for exclusive interviews, in-depth profiles and a frank look at gender representation in the industry today. Register now.
5
by Kyle LaHucik

At least 50 dif­fer­ent ven­ture in­vestors have ben­e­fit­ed from Eli Lil­ly’s deal­mak­ing this year, send­ing ear­ly in­vest­ment dol­lars back in­to the start­up ecosys­tem.

On Mon­day...

Read the full story
6
by Reynald Castaneda

GSK on Tues­day said it will start a late-stage tri­al of its mR­NA vac­cine for sea­son­al in­fluen­za af­ter the can­di­date de­liv­ered “high­er im­mune re­spons­es” than...

Read the full story